导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.02% | 2940/4763 |
| 近一周 | -1.85% | 2995/5452 |
| 近一月 | -3.61% | 2676/5409 |
| 近一季 | -7.13% | 2672/5219 |
| 近半年 | -2.86% | 2298/4908 |
| 近一年 | 0.46% | 2687/4388 |
| 近两年 | 44.53% | 1692/2951 |
| 近三年 | 26.23% | 1254/2250 |
| 成立以来 | 56.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.71% 3361/4961 |
11.83% 2287/5312 |
- - |
- - |
| 2025 | 18.93% 2272/4813 |
-1.10% 2580/3635 |
2.05% 1915/4076 |
17.81% 2428/4524 |
0.02% 2284/4813 |
| 2024 | 16.77% 766/3463 |
2.69% 727/2808 |
-1.23% 992/3014 |
16.77% 1355/3129 |
-1.41% 1693/3463 |
| 2023 | -9.49% 1174/2656 |
4.26% 1004/2280 |
-3.99% 995/2385 |
-3.03% 831/2515 |
-6.77% 1909/2655 |
| 2022 | -19.55% 866/2207 |
-13.87% 857/1919 |
6.60% 654/2016 |
-13.76% 967/2113 |
1.60% 1206/2208 |
| 2021 | -0.08% 738/1822 |
-2.54% 665/1255 |
5.94% 781/1330 |
-4.89% 746/1466 |
1.75% 810/1822 |
| 2020 | 36.65% 388/1250 |
-8.83% 633/1028 |
13.94% 583/1067 |
15.74% 198/1164 |
13.67% 341/1184 |
| 2019 | 38.42% 309/1092 |
27.08% 360/754 |
0.27% 183/804 |
1.19% 424/850 |
7.35% 445/918 |
| 2018 | -21.36% 210/834 |
- - |
- - |
- - |
-11.80% 351/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富沪深300指数C(LOF)C VS. 长安沪深300非周期A(740101) |